Apatinib Plus Etoposide as Second- or Higher-Line Treatment in Recurrent or Metastatic Triple-Negative Breast Cancer: A Single-Arm, Open Label, Prospective, Phase II Clinical Trial

Last Updated: Wednesday, July 6, 2022

The effect and safety profile of apatinib and etoposide have been demonstrated in several clinical trials for the treatment of late-stage TNBC. In this study, authors investigated the potential effect of combination therapy of apatinib plus etoposide, and found a promising clinical effect and acceptable toxicity in recurrent or metastatic TNBC.

2022 ASCO Annual Meeting

Breast Cancer: Targets and Therapy

Central Nervous System Metastases from Triple-Negative Breast Cancer: Current Treatments and Future Prospective

Breast Cancer: Basic and Clinical Research

Implementation of risk-stratified breast cancer prevention with a polygenic risk score test in clinical practice

Critical Reviews in Oncology/Hematology

Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey

Breast Cancer Research and Treatment

Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer

European Journal of Cancer

Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort

Expert Review of Anticancer Therapy

The role of immune checkpoint inhibition in triple negative breast cancer

Therapeutic Advances in Medical Oncology

Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: First observations from an interdisciplinary breast cancer centre in Germany

Breast Cancer: Basic and Clinical Research

Real-world survival and treatment regimens across first- to third-line treatment for advanced triple-negative breast cancer

The ASCO Post

Current management of and future possibilities for triple negative breast cancer

ESMO Open

How I Treat Metastatic Triple-Negative Breast Cancer

Metastatic Triple-Negative Breast Cancer Resource Center

Apatinib Plus Etoposide as Second- or Higher-Line Treatment in Recurrent or Metastatic Triple-Negative Breast Cancer: A Single-Arm, Open Label, Prospective, Phase II Clinical Trial

Breast Cancer: Targets and Therapy

Central Nervous System Metastases from Triple-Negative Breast Cancer: Current Treatments and Future Prospective

Breast Cancer: Basic and Clinical Research

Implementation of risk-stratified breast cancer prevention with a polygenic risk score test in clinical practice

Critical Reviews in Oncology/Hematology

Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey

Breast Cancer Research and Treatment

Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer

European Journal of Cancer

Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort

Expert Review of Anticancer Therapy

The role of immune checkpoint inhibition in triple negative breast cancer

Therapeutic Advances in Medical Oncology

Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: First observations from an interdisciplinary breast cancer centre in Germany

Breast Cancer: Basic and Clinical Research

Real-world survival and treatment regimens across first- to third-line treatment for advanced triple-negative breast cancer

The ASCO Post

Current management of and future possibilities for triple negative breast cancer

ESMO Open

How I Treat Metastatic Triple-Negative Breast Cancer

Treatment of a Patient With AML and mTNBC

Patient With Lung Metastasis and HER2-Low Status: Evolving Treatment Options

Fast Facts #6: Immunotherapy and Endocrinopathies